市场调查报告书

止血剂市场预测:凝血酶·氧化再生纤维素系·复合止血剂·明胶系·胶原蛋白系·纤维蛋白胶

Hemostatic Agents Market - Forecast (2020 - 2025)

出版商 IndustryARC 商品编码 622673
出版日期 内容资讯 英文 104 Pages
商品交期: 2-3个工作天内
价格
止血剂市场预测:凝血酶·氧化再生纤维素系·复合止血剂·明胶系·胶原蛋白系·纤维蛋白胶 Hemostatic Agents Market - Forecast (2020 - 2025)
出版日期: 2020年03月11日内容资讯: 英文 104 Pages
简介

本报告提供全球止血剂的市场调查,汇整市场定义和概要,竞争环境与市场占有率,产品基准,市场的各种影响因素及市场机会分析,价值链,市场生命周期,类型·治疗区分·终端用户·地区/各主要国家趋势与市场规模的变化与预测,主要企业简介等资讯。

第1章 市场概要

第2章 摘要整理

第3章 市场环境

  • 市场占有率分析
  • 财务分析
  • 终端用户的分析
  • 产品基准
  • 专利分析

第4章 市场影响因素

  • 成长推进因素
  • 阻碍成长要素·课题
  • 市场魅力

第5章 策略性市场分析

  • 价值链分析
  • 市场机会分析
  • 产品生命周期
  • 价格分析

第6章 止血剂市场分析·预测:各类型

  • 简介
  • 凝血酶
  • 明胶系
  • 胶原蛋白系
  • 氧化再生纤维素系
  • 复合止血剂
  • 纤维蛋白胶
  • 其他

第7章 止血剂市场分析·预测:治疗类别

  • 简介
  • 心脏血管
  • 一般外科
  • 消化器官外科
  • 神经外科
  • 其他

第8章 止血剂市场分析·预测:各终端用户

  • 简介
  • 医院
  • 外科中心
  • 看护设施
  • 其他

第9章 止血剂市场分析·预测:各地区

  • 简介
  • 南北美洲
    • 美国
    • 加拿大
    • 墨西哥
    • 巴西
    • 其他
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 其他
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲 & 纽西兰
    • 韩国
    • 其他
  • 其他
    • 非洲
    • 中东

第10章 市场熵

第11章 企业简介

  • Baxter International Incorporation
  • C.R. Bard Incorporation
  • B.Braun Melsungen AG
  • Integra Life Sciences Corporation
  • Equimedical
  • Marine Polymer Technologies
  • Gelita GmbH
  • Johnson and Johnson Services Inc
  • Pfizer Inc
  • Advanced Medical Solutions Group
  • Vascular Solutions, Inc
  • Z-Medica LLC
  • Mallinckrodt Plc

第12章 附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: HCR 0091

Hemostats are instruments used to reduce or halt bleeding during a surgery. These can be enabled by the use of smearing pressure, stitching the bleeding or using thermal energy devices. Hemostats generally are used to clot the blood during surgical procedures. Technical advancements have increased the usage of topical hemostatic agents in an extensive variety of surgical situations. Make it into a different sentence. New tissue sealants and hemostats in the market have addressed issue related to tissue contamination with previous sealants. How the new tissue sealants are addressing the previous sealant. New tissue sealants helps in reducing tissue contamination. Global hemostatic agents market is estimated to grow at a CAGR of 7.1% to reach $8,347.9m by 2022.

The report analyzes the hemostatic agents market by type, by treatment and by end user. The market by types covered in the report are thrombin, gelatin, collagen, oxidized regenerated, fibrin sealants and combination hemostats. Fibrin Sealants are estimated to be the fastest growing hemostatic agents during the forecast period 2017-2022. The hemostatic agents market is also segmented by treatment which includes cardio vascular, general surgery, digestive and neuro-surgery. This report highlights the end users of hemostatic agents such as hospitals, surgery centers and nursing homes. The report estimates the size of the global market in value terms ($million).

The report provides market size and forecast for APAC, Europe, Americas and RoW. A detailed qualitative analysis of the factors responsible to driving and restraining growth of the hemostatic agents market and future opportunities are provided in the report. The report profiles thirteen key players of the hemostatic agents market.

Sample Companies Profiled in this Report are:

Johnson & Johnson Services, Inc. (U.S.)

Baxter International Incorporation (U.S.)

C.R. Bard Incorporation (U.S.)

B.Braun Melsungen AG (Germany)

Advanced Medical Solutions Group (U.K.)

10+.

1. Hemostatic Agents Market Overview

2. Hemostatic Agents Market Executive Summary

3. Hemostatic Agents Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Financial Analysis
  • 3.3. End User Profiling
  • 3.4. Product Benchmarking
  • 3.5. Patent Analysis

4. Hemostatic Agents Market Forces

  • 4.1. Market Drivers
  • 4.2. Market Constraints & Challenges
  • 4.3. Attractiveness of Hemostatic Agents Market
    • 4.3.1. Power of Suppliers
    • 4.3.2. Power of Buyers
    • 4.3.3. Threat of Substitutes
    • 4.3.4. Threat of New entrants
    • 4.3.5. Degree of Competitive Rivalry

5. Hemostatic Agents Market- Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Opportunities Analysis
  • 5.3. Market Life Cycle Analysis
  • 5.4. Pricing Analysis

6. Hemostatic Agents Market - By Type

  • 6.1. Introduction
  • 6.2. Thrombin Based Hemostats
  • 6.3. Gelatin Based Hemostats
  • 6.4. Collagen Based Hemostats
  • 6.5. Oxidized Regenerated Cellulose Based Hemostats
  • 6.6. Combination Hemostats
  • 6.7. Fibrin Sealants
  • 6.8. Others

7. Hemostatic Agents Market - By Treatment

  • 7.1. Introduction
  • 7.2. Cardiovascular
  • 7.3. General Surgery
  • 7.4. Digestive Surgery
  • 7.5. Neurosurgery
  • 7.6. Others

8. Hemostatic Agents Market - By End User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Surgery Centers
  • 8.4. Nursing Homes
  • 8.5. Others

9. Hemostatic Agents Market -Geographic Analysis

  • 9.1. Introduction
  • 9.2. Americas
    • 9.2.1. U.S
    • 9.2.2. Canada
    • 9.2.3. Mexico
    • 9.2.4. Brazil
    • 9.2.5. Rest of Americas
  • 9.3. Europe
    • 9.3.1. U.K.
    • 9.3.2. Germany
    • 9.3.3. France
    • 9.3.4. Italy
    • 9.3.5. Rest of Europe
  • 9.4. Asia-Pacific
    • 9.4.1. China
    • 9.4.2. Japan
    • 9.4.3. India
    • 9.4.4. Australia & New Zealand
    • 9.4.5. South Korea
    • 9.4.6. Rest of APAC
  • 9.5. RoW
    • 9.5.1. Africa
    • 9.5.2. Middle East

10. Hemostatic Agents Market Entropy

11. Hemostatic Agents Market Company Profiles

  • 11.1. Baxter International Incorporation (U.S.)
  • 11.2. C.R. Bard Incorporation (U.S.)
  • 11.3. B.Braun Melsungen AG (Germany)
  • 11.4. Integra Life Sciences Corporation (U.S.)
  • 11.5. Equimedical (Netherlands)
  • 11.6. Marine Polymer Technologies (U.S.)
  • 11.7. Gelita GmbH (Germany)
  • 11.8. Johnson and Johnson Services Inc (U.S.)
  • 11.9. Pfizer Inc (U.S.)
  • 11.10. Advanced Medical Solutions Group (U.K.)
  • 11.11. Vascular Solutions, Inc (U.S.)
  • 11.12. Z-Medica LLC (U.S.)
  • 11.13. Mallinckrodt Plc (U.S.)

More than 10 Companies are profiled in this Research Report*

"*Financials would be provided on a best efforts basis for private companies"

12. Appendix

  • 12.1. Abbreviations
  • 12.2. Sources
  • 12.3. Research Methodology
  • 12.4. Bibliography
  • 12.5. Compilation of Expert Insights
  • 12.6. Disclaimer